Loading stock data…
TARS
$59.65-1.56 (-2.55%)
Market ClosedLast close May 11
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $59.65. The stock is currently 30% below its 52-week high of $85.25, remaining 10.6% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why TARS maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$59.65
Potential Upside
5%
Whystock Fair Value$62.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$94.22+58.0%
Range$88.00 – $100.00
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.44%
Volume
Today's trading volume
820,095
Recent News
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains
How Tarsus Pharmaceuticals stock has been trading Tarsus Pharmaceuticals (TARS) has caught investor attention after a recent stretch of weak trading, with the stock down 2.5% over the past day, 7.6% over the past week, and 17.8% over the past month. See our latest analysis for Tarsus Pharmaceuticals. At a share price of $59.65, Tarsus Pharmaceuticals has seen recent share price momentum fade, with weaker short term returns set against a much stronger backdrop that includes a 1 year total...
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?
If you are asking whether Tarsus Pharmaceuticals at around US$61.21 is offering good value or asking too much, the next sections will break down what the current price really implies. The stock has been volatile recently, with the share price down 5.2% over the last week and 15.6% over the last month, despite still sitting 38.5% higher over the past year and showing a very large 3 year return of 269.6%. These moves have kept Tarsus Pharmaceuticals on many investors' watchlists, as the price...
Tarsus Pharmaceuticals Q1 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) reported first-quarter 2026 results highlighted by continued commercial momentum for XDEMVY and progress across its development pipeline, including newly initiated and advancing Phase II programs in Lyme disease prevention and ocular rosacea. XDEMVY sales climb
Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Tarsus Pharmaceuticals, Inc.'s Q1 2026 earnings call
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +64.91% and +9.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?